Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immuneering Corp

3.47
+0.04001.17%
Volume:114.70K
Turnover:393.54K
Market Cap:124.87M
PE:-1.77
High:3.49
Open:3.38
Low:3.37
Close:3.43
Loading ...

Immuneering Elects New Directors at Annual Meeting

TIPRANKS
·
16 Jun

Immuneering Corporation Conducted Annual Stockholders Meeting

Reuters
·
16 Jun

Immuneering Corporation to Share Phase 2a Clinical Trial Updates on IMM-1-104 for Pancreatic Cancer on June 17, 2025

Reuters
·
16 Jun

Immuneering Price Target Maintained With a $9.00/Share by Needham

Dow Jones
·
05 Jun

Positive Buy Rating for Immuneering Driven by Promising Clinical Data and Competitive Positioning

TIPRANKS
·
05 Jun

Immuneering Corporation to Present at Jefferies Global Healthcare Conference in New York City

Reuters
·
29 May

Immuneering Is Maintained at Outperform by Oppenheimer

Dow Jones
·
07 May

Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data

TIPRANKS
·
07 May

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 May

Immuneering Q1 EPS $(0.42) Beats $(0.58) Estimate

Benzinga
·
06 May

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
06 May

Immuneering Price Target Maintained With a $12.00/Share by Needham

Dow Jones
·
10 Apr

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
24 Mar

Immuneering Corp. Reports Promising Cancer Trial Results

TIPRANKS
·
22 Mar

Press Release: Immuneering Corporation Announces Grant of Inducement Award

Dow Jones
·
22 Mar

Immuneering Price Target Maintained With a $12.00/Share by Needham

Dow Jones
·
21 Mar

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Dow Jones
·
21 Mar

BRIEF-Immuneering Corporation Q4 Net Income USD 18.1 Million

Reuters
·
21 Mar

Immuneering Q4 EPS $(0.58) Misses $(0.46) Estimate

Benzinga
·
21 Mar

Press Release: Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Dow Jones
·
20 Mar